MedTrace Logo

Pembrolizumab in Early Stage Colon Cancer

NCT04231526 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-07-31

No results posted yet for this study

Summary

This study will gather information on the safety and effectiveness of pembrolizumab, an immunotherapy drug. The purpose of this study is to target early stage colon cancer before it has developed resistance to immunotherapy.

Conditions

Interventions

DRUG

Pembrolizumab

2 cycles of neoadjuvant pembrolizumab (200mg IV every 21 days)

PROCEDURE

Surgery

Standard of care surgery

Sponsors & Collaborators

Principal Investigators

  • Daniel Catenacci, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2022-12-01
Completion
2022-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04231526 on ClinicalTrials.gov